PharmaLundensis AB (XSAT:PHAL) 3-1 Month Momentum %: -63.57% (As of Sep. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:PHAL PharmaLundensis AB XSAT:PHAL
18 GF Score
Price kr0.32
! 1 Warning Sign
View Full Analysis

What is PharmaLundensis AB 3-1 Month Momentum %?

PharmaLundensis AB XSAT:PHAL 18 3-1 Month Momentum % is -63.57% as of Sep. 05, 2026. GuruFocus rates XSAT:PHAL with a GF Score™ of 18/100. The stock has 1 warning sign investors should review. Among 1,387 Biotechnology companies, PharmaLundensis AB ranks worse than 97.55% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-05), PharmaLundensis AB's 3-1 Month Momentum % is -63.57%.

The industry rank for PharmaLundensis AB's 3-1 Month Momentum % or its related term are showing as below:

XSAT:PHAL's 3-1 Month Momentum % is ranked worse than
97.55% of 1387 companies
in the Biotechnology industry
Industry Median: -5.77 vs XSAT:PHAL: -63.57

PharmaLundensis AB  (XSAT:PHAL) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


PharmaLundensis AB 3-1 Month Momentum % Related Terms


XSAT:PHAL vs VRTX, REGN, RVMD: 3-1 Month Momentum % Comparison

For the Biotechnology subindustry, PharmaLundensis AB's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaLundensis AB 3-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaLundensis AB's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where PharmaLundensis AB's 3-1 Month Momentum % falls into.


XSAT:PHAL
18GF Score
PharmaLundensis AB XSAT:PHAL
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaLundensis AB  (XSAT:PHAL) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of -63.57% mean?
PharmaLundensis AB (XSAT:PHAL) has a 3-1 Month Momentum % of -63.57% as of Sep. 05, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on PharmaLundensis AB and its competitors. According to the industry distribution chart, PharmaLundensis AB ranks #1353 out of 1387 companies in the Biotechnology industry, placing it in the top 97.5%.
Is PharmaLundensis AB's 3-1 Month Momentum % too high?
PharmaLundensis AB's current 3-1 Month Momentum % is -63.57%. Based on the distribution chart, PharmaLundensis AB ranks #1353 out of 1387 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, PharmaLundensis AB has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does PharmaLundensis AB's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PharmaLundensis AB ranks #1353 out of 1387 companies for 3-1 Month Momentum %. This places PharmaLundensis AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on PharmaLundensis AB and its competitors. PharmaLundensis AB's current 3-1 Month Momentum % is -63.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaLundensis AB stock overvalued right now?
PharmaLundensis AB (XSAT:PHAL) has a current 3-1 Month Momentum % of -63.57%. The current 3-1 Month Momentum % is -63.57%. PharmaLundensis AB's overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For PharmaLundensis AB (XSAT:PHAL), the current 3-1 Month Momentum % is -63.57% as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaLundensis AB Business Description

Address PharmaLundensis AB, Scheelevagen 2, Lund, SWE, 223 63
PharmaLundensis AB is a Sweden based drug manufacturing company, The company focuses on the development and marketing of pharmaceuticals. It is engaged in developing drugs for the lung diseases, such as chronic obstructive pulmonary disease and asthma, as well as drugs for mercury toxicology.
18GF Score

Get the complete analysis for XSAT:PHAL

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.32
Price